Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

BACKGROUND First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone in a phase 2 trial. METHODS In this double-blind, phase 3 trial, we randomly assigned (in a 2: 1 ratio) 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations who had received no previous treatment for metastatic disease to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo every 3 weeks for 4 cycles, followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy. Crossover to pembrolizumab monotherapy was permitted among the patients in the placebo-combination group who had verified disease progression. The primary end points were overall survival and progression-free survival, as assessed by blinded, independent central radiologic review. RESULTS After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab-combination group versus 49.4% (95% CI, 42.1 to 56.2) in the placebocombination group (hazard ratio for death, 0.49; 95% CI, 0.38 to 0.64; P<0.001). Improvement in overall survival was seen across all PD-L1 categories that were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001). Adverse events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group and in 65.8% of those in the placebo-combination group. CONCLUSIONS In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significantly longer overall survival and progression-free survival than chemotherapy alone.Peer reviewe

Causa criminal sobre el atentado sedicioso contra la autoridad, asesinato del Teniente Alcalde Manuel de Tapia y heridas graves a varios indiviuos de la patrulla en la noche del 1º de noviembre de 1857 Pueblo de Miranda del Castañar : Juzgado de 1ª Instancia de Sequeros

Copia digital. Valladolid : Junta de Castilla y León. Consejería de Cultura y Turismo, 2009-201

Eugene Leitensdorfer

45-2ClaimsOn the Relief of E. Leitensdorfer. [1822] Induced the Pueblo Indians of New Mexico to remain peaceful during the U.S. invasion of Mexico in 1846-1847.1878-2

Appropriations -- New offices, &c. Report of the Clerk of the House of Representatives of the United States, in compliance with the "Act to authorize the appointment of additional paymasters, and for other purposes," passed July 4, 1836

24-2Appropriations in 1837. [304] Indian expenses.1837-5

Sundry Civil Appropriation Bill

50-1Sundry Civil Appropriation Bill. [2517] Year ending 30 June 1889; payments for the Peoria, Piankeshaw, Wea, and Kaskaskia Indians.1888-33

Mission of Saint James, in Washington Territory

44-1Private Land ClaimsReport on the Mission of St. James, Washington Territory. [1708] Land claims of a missionary society there to teach the Indians.1876-5

Volunteers -- Indian War -- Washington Territory

34-3Military AffairsReport on Volunteers in Washington Territory. [914] Indian war; restrained the Klickatat Indians from joing the war along with the Yakamas.1857-3

Cadwallader Wallace

27-2Public LandsReport : Petition of C. Wallace. [407] Virginia reservation in Ohio; Indian boundary line.1842-2